title: Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy.
abstract: OBJECTIVE
  The objectives of this study were to investigate the incidences of hepatitis B virus (HBV) reactivation and hepatitis in gastrointestinal cancer patients with positive hepatitis B surface antigen (HBsAg) after chemotherapy and assess the effect of antiviral therapy on preventing HBV reactivation and hepatitis.
  
  
  METHODS
  The medical records of gastric or colorectal cancer patients with positive HBsAg undergoing chemotherapy in West China Hospital were reviewed from January 2009 to August 2014.
  
  
  RESULTS
  One hundred and fifty-six patients were included. Seventy-six patients had no records of the baseline HBV DNA copy (bHDC) and received no antiviral therapy. Of 80 patients with known bHDCs, 39 patients received antiviral therapy. The incidence of HBV reactivation was 14.6% in the non-antiviral group with known bHDCs (n = 41), compared with 0% in the antiviral group (P = 0.039). Compared with 12.8% in the antiviral group (P = 0.034), 29.9% of patients suffered from hepatitis in the total non-antiviral group (n = 117). More patients with moderate/severe hepatitis were seen in the non-antiviral group (P = 0.027). Non-antiviral therapy was the only risk factor for hepatitis in multivariate analysis (HR 3.195, 95% CI 1.117-10.989; P = 0.043).
  
  
  CONCLUSIONS
  HBV reactivation and hepatitis occurred in a significant proportion of gastrointestinal cancer patients with positive HBsAg who received chemotherapy. Antiviral therapy could reduce the incidences of HBV reactivation and hepatitis.
authors: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China.
authors: Yu
authors: Y
authors: Yang
authors: Yang
authors: Y
authors: Du
authors: Wu-Xia
authors: WX
authors: Luo
authors: Cong
authors: C
authors: Li
authors: Ye
authors: Y
authors: Chen
authors: Ke
authors: K
authors: Cheng
authors: Jing
authors: J
authors: Ding
authors: Yi
authors: Y
authors: Zhou
authors: Jun
authors: J
authors: Ge
authors: Xian
authors: X
authors: Yang
authors: Ji-Yan
authors: JY
authors: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006505:Hepatitis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D012189:Retrospective Studies; D014775:Virus Activation / Q000187:drug effects; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens